| scholarly article | Q13442814 |
| P50 | author | Mien-Chie Hung | Q1532952 |
| Gabriel N Hortobagyi | Q88225186 | ||
| Massimo Cristofanilli | Q91695610 | ||
| P2093 | author name string | Francisco J Esteva | |
| Dongwei Zhang | |||
| Ping Liu | |||
| Naoto T Ueno | |||
| Savitri Krishnamurthy | |||
| Anthony Lucci | |||
| Balraj Singh | |||
| Tiffany A LaFortune | |||
| P2860 | cites work | Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants | Q24801016 |
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo | Q28368373 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Epithelial-mesenchymal transitions in development and pathologies | Q29614986 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Regulation of transcription by MAP kinase cascades | Q29618477 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Epidemiology of inflammatory breast cancer (IBC). | Q33781315 | ||
| Update on the management of inflammatory breast cancer | Q35108008 | ||
| Inflammatory breast cancer: a review | Q36121844 | ||
| Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas | Q36291695 | ||
| Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. | Q36618907 | ||
| ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation | Q36647913 | ||
| Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells | Q36852254 | ||
| Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity | Q37015793 | ||
| Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype | Q40012189 | ||
| COX-2 involvement in breast cancer metastasis to bone | Q40184738 | ||
| Expression profiling of epithelial plasticity in tumor progression | Q40625666 | ||
| Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade | Q40629608 | ||
| Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. | Q40727746 | ||
| Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. | Q41093419 | ||
| Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. | Q43586088 | ||
| Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor | Q45000490 | ||
| Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models | Q45103581 | ||
| Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. | Q46531450 | ||
| Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy | Q46610633 | ||
| Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy | Q46796554 | ||
| Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models | Q46857082 | ||
| Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. | Q46901734 | ||
| Epidermal growth factor receptors in lung tumours | Q69426534 | ||
| Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program | Q69833744 | ||
| Epidermal growth factor receptor in human breast cancer comparison with steroid receptors and other prognostic factors | Q70872137 | ||
| Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer | Q70997826 | ||
| Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer | Q73937563 | ||
| Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer | Q79918235 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| inflammatory breast cancer | Q5922406 | ||
| P304 | page(s) | 6639-6648 | |
| P577 | publication date | 2009-10-13 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer | |
| P478 | volume | 15 |
| Q37211807 | -216G/T (rs712829), a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma |
| Q36962901 | A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer |
| Q24626194 | A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer |
| Q36795486 | A view on EGFR-targeted therapies from the oncogene-addiction perspective. |
| Q33770856 | AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models |
| Q90429851 | An In Vitro Model of Triple-Negative Breast Cancer |
| Q35829855 | Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration |
| Q36359519 | Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases |
| Q35558027 | Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition |
| Q55322297 | CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. |
| Q42735675 | Cancer stem cell subsets and their relationships |
| Q33760216 | Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer |
| Q28554790 | Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine |
| Q34456201 | Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays |
| Q37690619 | Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers |
| Q49124045 | Conditioned Medium from Adipose-Derived Stem Cells (ADSCs) Promotes Epithelial-to-Mesenchymal-Like Transition (EMT-Like) in Glioma Cells In vitro |
| Q36706840 | Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities |
| Q92153761 | E2F1 Drives Breast Cancer Metastasis by Regulating the Target Gene FGF13 and Altering Cell Migration |
| Q36824370 | EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast |
| Q39111192 | EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas |
| Q36360133 | EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation |
| Q42243028 | EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer |
| Q37362586 | EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells |
| Q39167876 | Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer |
| Q37270040 | Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis |
| Q33927493 | ErbB/EGF signaling and EMT in mammary development and breast cancer |
| Q38862668 | Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment |
| Q39727786 | Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer |
| Q36657315 | Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression |
| Q34287510 | Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents |
| Q44586994 | How do I treat inflammatory breast cancer? |
| Q64228655 | Identification of Biologically Active Compounds and Synthesis of Improved Derivatives That Confer Anti-cancer Activities |
| Q36356354 | Identification of epidermal growth factor receptor and its inhibitory microRNA141 as novel targets of Krüppel-like factor 8 in breast cancer |
| Q38555670 | Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines. |
| Q63366138 | Inflammatory breast cancer biology: the tumour microenvironment is key |
| Q37642845 | Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells. |
| Q35983594 | Local iontophoretic administration of cytotoxic therapies to solid tumors |
| Q35313206 | Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model |
| Q42513445 | Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway. |
| Q30528547 | Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells |
| Q91783003 | Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium |
| Q39693833 | Preneoplastic changes persist after IGF-IR downregulation and tumor regression |
| Q53312576 | Quantification of epidermal growth factor receptor (EGFR) in canine mammary tumours by ELISA assay: clinical and prognostic implications. |
| Q54976875 | RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. |
| Q39426062 | RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro |
| Q47100005 | Risk Factors and Preventions of Breast Cancer |
| Q37320346 | Role of epidermal growth factor receptor in breast cancer |
| Q63366144 | Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer |
| Q45916506 | Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. |
| Q28730146 | Selection of metastatic breast cancer cells based on adaptability of their metabolic state |
| Q34711378 | Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer |
| Q64890079 | Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. |
| Q36430004 | Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells |
| Q53090999 | TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. |
| Q58117324 | Targeted Nanomedicine to Treat Bone Metastasis |
| Q34117454 | Targeted therapy in inflammatory breast cancer |
| Q42766317 | Targeting EGFR in Triple Negative Breast Cancer |
| Q42369599 | The Third International Inflammatory Breast Cancer Conference |
| Q34419629 | The role of inflammation in inflammatory breast cancer. |
| Q36900976 | Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFR-PAR1-Pak1 pathway |
Search more.